Protein Clearance Mechanisms of Alpha-Synuclein and Amyloid-Beta in Lewy Body Disorders by Deleidi, Michela & Maetzler, Walter
Hindawi Publishing Corporation
International Journal of Alzheimer’s Disease
Volume 2012, Article ID 391438, 9 pages
doi:10.1155/2012/391438
Review Article
Protein Clearance Mechanisms of Alpha-Synuclein and
Amyloid-Beta in Lewy Body Disorders
Michela Deleidi1 and Walter Maetzler1, 2
1German Center for Neurodegenerative Diseases (DZNE), University of Tuebingen, 72076 Tuebingen, Germany
2Center of Neurology, Department of Neurodegeneration, Hertie Institute for Clinical Brain Research,
University of Tuebingen, Hoppe Seyler-Straße 3, 72076 Tuebingen, Germany
Correspondence should be addressed to Walter Maetzler, walter.maetzler@uni-tuebingen.de
Received 28 May 2012; Accepted 30 August 2012
Academic Editor: Taher Darreh-Shori
Copyright © 2012 M. Deleidi and W. Maetzler. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Protein clearance is critical for the maintenance of the integrity of neuronal cells, and there is accumulating evidence that
in most—if not all—neurodegenerative disorders, impaired protein clearance fundamentally contributes to functional and
structural alterations eventually leading to clinical symptoms. Dysfunction of protein clearance leads to intra- and extraneuronal
accumulation of misfolded proteins and aggregates. The pathological hallmark of Lewy body disorders (LBDs) is the abnormal
accumulation ofmisfolded proteins such as alpha-synuclein (Asyn) and amyloid-beta (Abeta) in a specific subset of neurons, which
in turn has been related to deficits in protein clearance. In this paper we will highlight common intraneuronal (including autophagy
and unfolded protein stress response) and extraneuronal (including interaction of neurons with astrocytes and microglia,
phagocytic clearance, autoimmunity, cerebrospinal fluid transport, and transport across the blood-brain barrier) protein clearance
mechanisms, which may be altered across the spectrum of LBDs. A better understanding of the pathways underlying protein
clearance—in particular of Asyn and Abeta—in LBDs may result in the identification of novel biomarkers for disease onset and
progression and of new therapeutic targets.
1. Introduction
Lewy body disorders (LBDs) is an umbrella term that
includes diseases with alpha-synuclein (Asyn) aggregates as
fibrils in Lewy bodies (LBs) and Lewy neurites. Several lines
of evidence support a pathogenic role of misfolded Asyn
in LBDs [1–3]. Parkinson’s disease (PD) without dementia
(PDND) is the most common subtype of LBDs, followed by
PD with dementia (PDD) and dementia with Lewy bodies
(DLBs) [4, 5]. Like in PD, the core feature of PDD is a
diagnosis of PD according to the UK Brain Bank Society
criteria [6] but also includes cognitive symptoms severe
enough to fulfil dementia criteria at least one year after
PD diagnosis with insidious onset, slow progression, and
impairment in more than one cognitive domain [7]. DLB
is the second most prevalent neurodegenerative dementia
after Alzheimer’s disease (AD). Clinical diagnosis is based
on the presence of a dementia syndrome, accompanied by at
least two out of the three following symptoms: fluctuating
cognition with pronounced variations in attention and
alertness, visual hallucinations, and Parkinsonism [8]. In
contrast to PDD, the onset of dementia in DLB is before or
within one year of any Parkinsonism.
About one-fourth of LBDs patients show cortical amy-
loid-beta (Abeta) deposition, with the highest proportion in
DLB subjects, followed by PDD subjects [9–14]. According
to clinical, neuroimaging, and neuropathological data, co-
occurrence of Asyn and Abeta is regularly associated with
dementia in LBDs [13–15].
Based on the central role that Asyn and Abeta play in the
pathogenesis of LBDs and the increasing body of literature
pointing to defective clearance of misfolded proteins as a key
mechanism to the pathogenesis of LBDs, this paper aims at
providing a condensed review of this latter topic. Although
not exhaustive, it may provide a basic understanding of such
mechanisms eventually contributing to the development of
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novel disease biomarkers (which are currently not available
[16, 17]) and neuromodulatory treatment strategies for these
still incurable and chronic diseases.
2. General Mechanisms of Protein Clearance
The main (intraneuronal) pathways for the degradation and
recycling of proteins are the ubiquitin/proteasome system
(UPS) and the autophagy-lysosomal pathway (macroauto-
phagy, microautophagy, and chaperone-mediated autophagy
(CMA)).
The UPS degrades short-lived nuclear and cytosolic
proteins or misfolded proteins in the endoplasmic reticulum
[18]. It plays a key role in signal transduction, cell cycle pro-
gression, apoptosis, and cellular diﬀerentiation and has been
implicated in several human diseases, including neurodegen-
erative diseases, cancer, inflammation, and autoimmunity
[18–20].
Autophagy is a process involving the degradation of
components inside lysosomes [21, 22]. It has a variety of
physiological and pathophysiological roles in protein and
organelle clearance, development, defence against microor-
ganisms, cell death, and antigen presentation [23]. In
macroautophagy, organelles and macromolecular compo-
nents are first surrounded by a double membrane, defined
as the autophagosome or autophagic vacuole (AV), which
then fuses with lysosomes to form autolysosomes. In
microautophagy, the transfer of cytosolic components the
lysosomal compartment happens by direct invagination of
the lysosomal membrane without prior sequestration into
the autophagosome. Finally, in CMA, individual proteins are
targeted to lysosomes by the binding of a hsc70-containing
chaperone/cochaperone complex.
All these pathways are observable in neurons, and both
impairment and excessive activation of these pathways are
linked to neurodegenerative processes [24].
(Extraneuronal) clearance pathways include interaction
of neurons with astro- and microglia and with infiltrating
macrophages. Microglial cells are considered the professional
phagocytes in the brain. However, other populations of cells
may also act as phagocytes, including astrocytes, neural stem
cells, and neurons [25–28]. There is no clear evidence for
a defective protein clearance by the brain innate immune
system as a primary pathogenetic event in neurodegenerative
diseases. However, phagocytosis of misfolded proteins by
astro- and microglia triggers the release of proinflammatory
cytokines and chemokines and reactive oxygen/nitrogen
species, which may, under pathological conditions, further
promote neuronal dysfunction and degeneration [29, 30].
The adaptive immune system is also involved in
the clearance of misfolded proteins in the brain. Nat-
urally occurring autoantibodies are detectable in body
fluids of healthy controls and in patients with neurode-
generative disorders [31–33]. Finally, protein transport
from the parenchyma to the cerebrospinal fluid (CSF)
and across the blood-brain barrier are relevant clearance
mechanisms and have been shown to be aﬀected in
LBDs.
Intra- and extraneuronal clearance mechanisms closely
interact: as an example, protein aggregates can stimulate the
cell surface innate immune receptors, initiating intracellular
signaling cascades that, in turn, stimulate phagocytosis.
An overview of how these mechanisms may interact is
schematically illustrated in Figure 1.
In the following, all these mechanisms are discussed in
more detail with special emphasis on Asyn and Abeta clear-
ance.
3. Asyn Clearance
3.1. Intraneuronal Mechanisms. Abnormal deposition of
Asyn occurs early in the disease process of LBDs and may
follow an ascending pattern in most of the cases, starting
from lower brainstem areas and then aﬀecting limbic and
cortical areas [34]. Deposition may start even earlier in the
autonomic peripheral nervous system [35, 36]. The mech-
anisms responsible for Asyn degradation have been contro-
versial, but it appears that, under normal conditions, Asyn
is degraded by both the UPS and the autophagy-lysosomal
pathway [37–39], whereas the autophagy-lysosomal pathway
mediates clearance of accumulated and aggregated Asyn
[38]. In agreement with this observation, activation of
autophagy leads to increased wild-type Asyn clearance and
neuroprotection [37, 40]. Normal Asyn binds to the CMA-
specific receptor LAMP-2A on the lysosomal membrane and
is subsequently degraded by CMA. However, mutant forms
of Asyn (A53T and A30P) and Asyn modified by dopamine
tightly bind to the CMA receptors on the lysosomal mem-
brane and inhibit both their own degradation and that of
other CMA substrates [38, 41]. The dysfunction of CMA
triggers neuronal dysfunction and increases vulnerability
to stress. Interestingly, both mutant and wild-type Asyn
can decrease proteasomal activity and increase vulnerability
to neurodegeneration, leading to a vicious cycle where
an increased amount of intraneuronal Asyn can block its
clearance by itself [38, 42–46].
Several studies provide evidence for impaired autophagy-
mediated clearance mechanisms in PD. The main proteins
involved in CMA (Lamp2a and Hsc70) are decreased in
the SN and amygdala from PD patients [46]. Microtubule-
associated protein 1A/1B-light chain 3 (LC3, a marker for
autophagic vacuoles) colocalizes with Asyn in most LBs and
Lewy neurites [46].
Genetic mutations leading to Parkinsonism support the
hypothesis that defective clearance mechanisms are centrally
involved also in idiopathic forms of LBDs. Interaction
between PINK1 and Parkin can modulate mitophagy [47,
48]. PINK1 itself directly activates autophagy and inter-
acts with autophagic proteins such as Beclin1 [49]. A
reduced clearance of mitochondria was also demonstrated
in cells lacking DJ-1 which is another protein associated
with recessive forms of Parkinsonism [50]. Mutations in
the LRRK2 gene, the most common form of late onset
autosomal dominant Parkinsonism, may also cause neuronal
cell death via impairment of protein degradation path-
ways as they influence the autophagy-lysosomal pathway,
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Figure 1: Intra- and extraneuronal mechanisms of protein clearance. The main intracellular pathways for the degradation and recycling
of proteins are the ubiquitin/proteasome system (UPS) and the autophagy-lysosomal pathway (microautophagy, macroautophagy, and
chaperone-mediated autophagy (CMA)). Extracellular clearance pathways include interaction of neurons with astro- andmicroglia, and with
infiltrating macrophages, autoantibodies, and protein transport from the parenchyma to the cerebrospinal fluid and across the blood-brain
barrier. The engulfment of misfolded proteins by astro- and microglia triggers the release of proinflammatory cytokines and chemokines as
well as reactive oxygen/nitrogen species, whichmay, under pathological conditions, further promote neuronal dysfunction and degeneration.
leading to Asyn accumulation and aggregation [51, 52].
Heterozygous mutations in the gene encoding the lysosomal
enzyme glucocerebrosidase (GBA) convey an approximately
5-fold risk for PD. These mutations are associated with
lysosomal dysfunction and influence binding of Asyn to its
specific receptor at the lysosome membrane: a recent study
demonstrated that the accumulation of the GBA substrate
glucosylceramide stabilizes Asyn soluble oligomers which,
in turn, can inhibit normal GBA lysosomal activity. This
creates a positive feedback loop that could directly contribute
to the neurodegenerative process [53]. The heterozygous
GBA mutation also seems to directly influence fatty acid
metabolism: PD patients with these mutations have lower
CSF levels of palmitoleic, oleic, linoleic, arachidonic, eicos-
apentaenoic, and docosahexaenoic acids compared with both
idiopathic PD patients and controls [54].
3.2. Extraneuronal Mechanisms (Mainly) . Although Asyn is
a cytosolic protein, a low quantity of the protein is secreted
via vesicle exocytosis and is then present in biological
fluids including plasma and CSF [55–57]. The mechanisms
responsible for the extraneuronal clearance of Asyn are not
entirely clear; however, there is increasing evidence that
adjacent cells such as astrocytes and microglia as well as
the adaptive immune system and local protein transport
mechanisms are crucially involved.
Loss of midbrain dopaminergic neurons and stri-
atal degeneration can be preceded by neuroinflammation
marked by activated microglia and an increase in proin-
flammatory cytokines and chemokines [29, 30, 58–62].
Astrocytes are also involved in the initiation and progression
of the disease [63]. A recent study showed that astrocytic
Asyn initiates noncell autonomous killing of neurons [64].
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Indeed, extraneuronal forms of Asyn can activate glial cells
and trigger inflammation and subsequent release of proin-
flammatory molecules, a common pathological hallmark of
LBDs [60, 65]. Several studies have reported Asyn-containing
inclusions in astroglia of PD and DLB patients [66], and
phagocytic microglial cells are very eﬃcient scavengers of
extraneuronal Asyn aggregates [63, 67].
Results of recent GWAS studies argue for the relevance
of the immune system, in the pathophysiology of LBDs,
as variations in the human leukocyte antigen (HLA) region
were associated with occurrence of LBDs [68, 69]. This
may also be mediated through microglia as these cells are
capable of presenting antigens to lymphocytes [70] via
the HLA domain. Activation of HLA-positive microglia is
observable in aﬀected brain regions of PD patients [71]. Asyn
autoantibodies aremore prevalent in sera of PD patients than
in controls [31]. These results were basically confirmed by
a recent study where serum Asyn autoantibody levels were
higher in demented LBDs patients than in controls [72].
An overload of local Asyn can also occur due to defective
transport mechanisms of Asyn from the neuron to the
CSF. Most studies investigating CSF total Asyn levels in
PD showed that these levels are reduced in the CSF of
PD patients compared to controls, whereas oligomeric Asyn
levels seem to be higher in PD compared to control CSF
[57, 73–77]. A recent study showed that CSF levels of
phosphorylated Asyn correlate weakly with PD severity and,
if corrected for total Asyn, contributed to the diﬀerential
diagnosis between PD, multiple system atrophy (MSA), and
progressive supranuclear palsy (PSP) [78]. However, it is
neither clear to date how Asyn is transported from the
parenchyma to the CSF, nor why total Asyn is reduced and
pathological forms of Asyn are elevated in the CSF of PD
patients.
4. Abeta Clearance: Lessons from
Alzheimer’s Disease Research
Comparable to LBDs pathophysiology, in AD, only some rare
genetic mutations lead to increased APP expression or to
changes in Abeta stability or aggregation [79]. The common
late onset sporadic AD seems to be far better explained by
impaired Abeta clearance mechanisms [80]. Thus, assuming
that similar mechanisms may occur in (late onset) AD and
LBDs and that Abeta pathology is a pathophysiologically
relevant feature of LBDs, a discussion of (ineﬀective) Abeta
clearance mechanisms as they occur in AD may substantially
contribute to our understanding of how Abeta may (or may
not) be cleared in LBDs.
4.1. IntraneuronalMechanisms. There is convincing evidence
from electron microscopy studies [81] that the autophagy-
lysosomal pathway is involved in the pathogenesis of AD.
AVs which are the major reservoir of intraneuronal Abeta are
abundant in aﬀected neurons, especially in those with neu-
rofibrillary tangles [82]. These studies argue for an impaired
maturation of autophagolysosomes and impaired intraneu-
ronal retrograde transport in AD. Defective clearance of
Abeta-generating AVs may result in Abeta accumulation
[83, 84]. Several further findings corroborate the hypothesis
that impaired autophagy plays a key role in the pathogenesis
of neuronal degeneration in AD. Beclin1 is decreased in AD
brains, and decreased neuronal autophagy and subsequent
lysosomal dysfunction and neurodegeneration are observed
in mice carrying a heterozygous deletion of Beclin1 [85].
Presenilin 1 (PS1) is essential for maturation of the lysosomal
proton pump and aﬀects autophagocytosis and protein
turnover [86].
4.2. Extraneuronal Clearance Mechanisms (Mainly). Abeta
concentration is tightly regulated by amyloid-degrading
proteolytic enzymes and perivascular drainage [87–89].
Neprilysin (NEP) is an Abeta-degrading protein found at
presynaptic terminals and in body fluids [90, 91]. It is
a preferentially membrane-bound, presynaptically located
protein with an extracellular catalytic site which can degrade
Abeta [90, 91]. A soluble form of NEP is detectable in body
fluids such as blood and CSF, emanating from a slow release
from the membranes [92]. Most interestingly, reduced CSF
NEP activity levels have been shown to occur in early AD
[93, 94].
Another protein involved in defective clearance mecha-
nisms in AD is cystatin C. Neurons, among other cells, are
able to produce and secrete this protein [95]. Fourfold higher
levels of cystatin C in the CSF than in blood [96] indicate
a relevant role of the protein in CNS pathways. Cystatin C
binds monomeric Abeta and carries soluble Abeta [97, 98].
There is evidence that AD patients have reduced CSF cystatin
C levels [99, 100]. This makes it intriguing to hypothesize
that a deficient Abeta-binding capacity, as induced by a lack
of (functional) cystatin C, may contribute to the amyloido-
genic process in AD [99]. Indeed, increased expression of this
protein has been shown to reduce parenchymal Abeta load in
mouse models of AD [101, 102]. Of note, the BB genotype
of the cystatin C-encoding gene—which leads to reduced
cystatin C secretion from the neuron to the extracellular
space [103, 104]—conveys susceptibility to AD [105].
Inflammatory reactions, characterized by activated mic-
roglia and astrocytes surrounding amyloid deposits, are
intimately associated with the onset and progress of AD
[106–108]. Reactive astrocytes with Abeta-positive granules
are found in close proximity to amyloid plaques. Human
astrocytes express scavenger receptors and several Abeta-
degrading enzymes such as NEP, insulin-degrading enzyme
(IDE), endothelin-converting enzyme (ECE), angiotensin-
converting enzyme (ACE), plasminogen activators, and the
matrix metalloproteinases-9 and -2 (MMP-9, MMP-2) [109–
112]. These findings suggest an important role of astrocytes
in Abeta clearance.
Clinicopathological studies suggest that microglial acti-
vation is an early event in AD pathology [113, 114].
Activated microglia surround amyloid fibril deposits, and
postmortem studies have shown significant amounts of
Abeta in microglial cells of AD patients treated with
immunization therapy [115, 116]. Microglia express toll-like
receptors (TLRs), a family of highly conservedmolecules that
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recognize pathogen-associated molecular patterns, including
both exogenous and endogenous ligands [117]. TLR2 and
TLR4 have been associated with the removal of Abeta,
indicating that the innate immune system plays a key role in
preventing the brain from Abeta deposits [118–120].
In addition, the adaptive immune system is obviously
involved in CNS parenchyma clearance mechanisms. Nat-
urally occurring antibodies directed against Abeta have
been detected in the CSF and plasma of patients with
AD and healthy control subjects. Some studies have shown
reduced CSF levels of anti-Abeta antibodies in patients
with AD compared with healthy control subjects [32, 121]
and in individuals at increased risk for AD [122]. Another
study reported that a subset of conformation-specific, cross-
reactive antibodies that may protect against amyloidogenic
toxic peptides are reduced in AD patients [123]. As a
consequence of these findings, a number of phase II and III
clinical trials are currently under way to test the eﬀect of
such autoantibodies in AD patients [124]. First results are
promising: a recent study using carbon 11-labeled Pittsburgh
Compound B ([11C]PiB) positron emission tomography
(PET) has shown that passive immunization can reduce the
level of brain amyloid in vivo after 18 months of antibody
treatment [125].
5. Abeta Clearance in Lewy Body Disorders
5.1. Intraneuronal Mechanisms. To the best of our knowledge
there is no study available that investigated intraneuronal
mechanisms of Abeta clearance in LBDs. There is however
indirect evidence that deficits of (intraneuronal) defence
mechanisms against Abeta toxicity may exist, at least in
demented LBDs patients. We recently showed that CSF
levels of uric acid, an antioxidant detectable in neurons and
associated with PD progression, were significantly lower in
demented than in nondemented LBDs patients. In addition,
these levels correlated positively with CSF Abeta42 levels,
with highest correlation values in controls and lowest in
demented LBDs patients [126]. In the light of the recent
finding that CSF Abeta levels increase within hours after
trauma and thus reflect a suﬃcient and fast response to
neuronal stress [127], a weak correlation of CSF Abeta42
with uric acid may indicate deficits in this repair mechanism.
5.2. Extraneuronal Mechanisms (Mainly). Lowered CSF NEP
activity levels have been found in demented LBDs patients,
compared to nondemented LBDs patients and controls
[128]. In addition, CSF NEP activity levels correlated
positively with CSF Abeta42. These data argue for a role of
NEP in the pathophysiology of cognitive decline in LBDs.
Also cystatin C seems to be relevantly involved in Abeta-
associated cognitive decline in LBDs. Our group investigated
CSF and serum levels in LBDs patients [129] and found
lower CSF cystatin C levels in demented LBDs patients
compared to PDND and controls. In additions, these levels
correlated positively with age at onset of dementia but not
with parameters associated with Parkinsonism. Notably, the
correlation between CSF cystatin C and CSF Abeta42 levels
was highly significant in nondemented individuals, but not
significant in demented patients. This indicates that cystatin
C-related Abeta transport from the neuron to the CSF is
impaired in demented LBDs patients. This hypothesis is
corroborated by genetic results [129]. The risk genotype of
the CST3 gene, BB, was detectable only in demented LBDs
patients and was associated with low CSF cystatin C levels.
The role of the innate immune system in Abeta clearance
in LBDs is not well understood although neuroinflammatory
reactions are a common finding in LBDs and are considered
to play a key role in the neurodegenerative process [63].
There is a tight association of microglia with degenerating
LB-containing neurons [130]. Activated microglia is associ-
ated with Asyn-positive oligodendrocytes in MSA patients
and in an animal model of this disease [131, 132]. Astrocytic
abnormalities also occur [133, 134].
The adaptive immune system is also involved in Abeta-
associated mechanisms in LBDs. Autoantibodies against
Abeta were elevated in serum and CSF of demented LBDs
patients, compared to controls and were even higher than
in other forms of dementia such vascular dementia [72].
Still, many questions remain about the contribution of the
immune system, such as microglia, macrophages, and T
cells but also other immune cells, to clearance of misfolded
proteins in the CNS.
6. Conclusion
Although many questions remain open, recent literature
suggests that impairment of protein clearance is one of the
key factors mediating the degeneration of vulnerable neu-
ronal populations in LBDs. Both intra- and extraneuronal
clearance mechanisms are impaired in LBDs. An improved
understanding of such pathways can provide the basis for
new developments in the biomarker era and, ultimately,
contribute to the development of neuromodulatory or even
causal treatment strategies.
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